Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
09.06. | Improving patients' mental health: the role of healthcare comms | ||
09.06. | The outlook for healthcare comms in 2025 | ||
06.06. | Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m | ||
06.06. | AstraZeneca's Calquence approved by EC for first-line chronic lymphocytic leukaemia use | ||
06.06. | Conferences: the value of real experience versus virtual convenience | ||
06.06. | The power of creativity in healthcare PR | ||
05.06. | Roche's Evrysdi tablets granted EC approval to treat spinal muscular atrophy | ||
05.06. | VML Health appoints Nick Bartlett as chief executive officer of EU hub | ||
05.06. | Essential agility in an era of change for medical affairs | ||
05.06. | How AI can humanise data and transform healthcare communications | ||
04.06. | Regeneron gains rights to Hansoh's GLP-1/GIP receptor agonist in deal worth $2bn | ||
04.06. | Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma | ||
04.06. | Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery | ||
04.06. | Inizio Evoke appoints Matthew Hoelzle as chief medical officer | ||
04.06. | Building inclusive clinical trials through policy reform | ||
04.06. | Turning cold facts into compassionate conversations: the power of patient-centricity in medical education | ||
03.06. | BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn | ||
03.06. | AstraZeneca's Forxiga recommended by NICE for wider chronic kidney disease use | ||
03.06. | Roche/Jazz Pharmaceuticals share positive phase 3 results for lung cancer combination therapy | ||
03.06. | Focusing on the patient voice to improve outcomes | ||
03.06. | How can we achieve the right balance of HCP engagements in medcomms? | ||
02.06. | Pfizer shares 'unprecedented' survival results for Braftovi in colorectal cancer | ||
02.06. | Sanofi to expand immunology capabilities with $9.5bn Blueprint Medicines acquisition | ||
02.06. | Eli Lilly's Omvoh recommended by NICE to treat Crohn's disease in adults | ||
02.06. | Between luck and leadership: success because of, not despite, strategy |